연구성과로 돌아가기
2020 연구자 정보 (22 / 997)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Catenacci, Daniel V. T. (Catenacci, DVT) |
제1저자 | 교신저자 | Univ Chicago, Med Ctr, Chicago, IL 60637 USA |
K-4177-2019 Catenacci, Daniel |
|
[JCR상위 1.9] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu; |
|
Chee, Cheng Ean (Chee, CE) |
Natl Univ Canc Inst, Singapore, Singapore |
|
|
[JCR상위 1.9] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu; | ||
|
Davidson-Moncada, Jan K. (Davidson-Moncada, JK) |
MacroGenics, Rockville, MD USA |
|
|
[JCR상위 1.9] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu; | ||
|
Enzinger, Peter C. (Enzinger, PC) |
Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA |
|
|
[JCR상위 1.9] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu; | ||
|
Franovic, Aleksandra (Franovic, A) |
Guardant Hlth Inc, Redwood City, CA USA |
|
|
[JCR상위 1.9] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu; | ||
|
Gold, Philip J. (Gold, PJ) |
Swedish Canc Inst, Seattle, WA USA |
|
|
[JCR상위 1.9] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu; | ||
|
Hochster, Howard S. (Hochster, HS) |
Yale Sch Med, New Haven, CT USA Rutgers Canc Inst New Jersey, New Brunswick, NJ USA |
|
|
[JCR상위 1.9] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu; | ||
|
Jeon, Hui-Jeon (Jeon, HJ) |
Daegu Gyeongbuk Med Innovat Fdn, New Drug Dev Ctr, Daegu 41061, South Korea |
|
|
[JCR상위 1.9] Inhibition of Glutamine Utilization Synergizes with Immune Checkpoint Inhibitor to Promote Antitumor Immunity | SCIE | 1.9 | BIOCHEMISTRY & MOLECULAR BIOLOGY;CELL BIOLOGY | ykchoi@knu.ac.kr;kpark@knu.ac.kr; | ||
|
Juergens, Rosalyn A. (Juergens, RA) |
McMaster Univ, Juravinski Canc Ctr, Hamilton, ON, Canada |
|
0000-0001-8627-4704 Juergens, Rosalyn |
[JCR상위 1.9] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu; | ||
|
Kelly, Ronan J. (Kelly, RJ) |
Baylor Univ, Med Ctr, Dallas, TX USA |
|
|
[JCR상위 1.9] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu; | ||
|
Kim, Jae Sun (Kim, JS) |
Sungkyunkwan Univ, Sch Med, Seoul 16419, South Korea |
|
|
[JCR상위 1.9] Inhibition of Glutamine Utilization Synergizes with Immune Checkpoint Inhibitor to Promote Antitumor Immunity | SCIE | 1.9 | BIOCHEMISTRY & MOLECULAR BIOLOGY;CELL BIOLOGY | ykchoi@knu.ac.kr;kpark@knu.ac.kr; | ||
|
Kim, Sunnie (Kim, S) |
Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA Univ Colorado, Ctr Canc, Aurora, CO USA |
J-2750-2012 Kim, Tae-You |
|
[JCR상위 1.9] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu; | ||
|
Knutson, Keith L. (Knutson, KL) |
Mayo Clin, Jacksonville, FL 32224 USA |
|
|
[JCR상위 1.9] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu; | ||
|
Lacy, Jill (Lacy, J) |
Yale Sch Med, New Haven, CT USA |
|
|
[JCR상위 1.9] Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial | SCIE | 1.9 | ONCOLOGY | dcatenac@bsd.uchicago.edu; | ||
|
Lee, Jaebon (Lee, J) |
Sungkyunkwan Univ, Sch Med, Seoul 16419, South Korea |
JNT-2600-2023 Lee, Jaebon |
|
[JCR상위 1.9] Inhibition of Glutamine Utilization Synergizes with Immune Checkpoint Inhibitor to Promote Antitumor Immunity | SCIE | 1.9 | BIOCHEMISTRY & MOLECULAR BIOLOGY;CELL BIOLOGY | ykchoi@knu.ac.kr;kpark@knu.ac.kr; |
페이지 이동: